

Vacuna Covid 19

Links a Texto completo Science Direct

<p>C.V. Herst, C. V. ... [et al.] (2020). An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. <i>Vaccine</i>, 38 (28), pp. 4464-4475. Recuperado de http://www.sciencedirect.com/science/article/pii/S0264410X20305181</p>
<p>Chu MD, D. K. ... [et al.] (2020). Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. <i>The Lancet</i>. Recuperado de http://www.sciencedirect.com/science/article/pii/S0140673620311429</p>
<p>Feng-Cai, Z. ... [et al.] (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. <i>The Lancet</i>, 395, 10240, pp. 1845-1854. Recuperado de https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31208-3.pdf</p>
<p>Global governance for COVID-19 vaccines. <i>The Lancet</i>, 395, 10241, p. 1883. Recuperado de http://www.sciencedirect.com/science/article/pii/S0140673620314057</p>
<p>Hosangadi, D. ... [et al.] (2020). Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic. <i>Vaccine</i>, 38 (26), pp. 4167-4169. Recuperado de https://www.sciencedirect.com/science/article/pii/S0264410X20305302?via%3Dihub</p>
<p>Lambert. P. H. ... [et al.] (2020). Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i>, 38 (31), pp. 4783-4791. Recuperado de http://www.sciencedirect.com/science/article/pii/S0264410X2030709X</p>
<p>Leung, K. ... [et al.] (2020). First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. <i>The Lancet</i>, 395, 10233, pp. 1382-1393. Recuperado de</p>

<http://www.sciencedirect.com/science/article/pii/S0140673620307467>

Muneeb, A. F., (2020). B-cell engineering: A promising approach towards vaccine development for COVID-19. *Medical Hypotheses*, 144, 109948, Recuperado de

<https://www.sciencedirect.com/science/article/pii/S030698772030791X?via%3DiHub>

Nelson, L. & McGeer, A. (2020). The starting line for COVID-19 vaccine development. *The Lancet*, 395, 10240, pp. 1815-1816. Recuperado de

<http://www.sciencedirect.com/science/article/pii/S0140673620312393>

Owen Schaefer, G; ... [et al.] (2020). COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?, *Vaccine*. Recuperado de

<http://www.sciencedirect.com/science/article/pii/S0264410X20307684>

Pagliusi, S. ... [et al.] (2020). Emerging Manufacturers engagements in the COVID -19 vaccine research, development and supply. *Vaccine*. Recuperado de

<http://www.sciencedirect.com/science/article/pii/S0264410X20307957>

Parismita, K. ... [et al.] (2020). Design of a peptide-based subunit vaccine against novel coronavirus SARSCoV-2. *Microbial Pathogenesis*, 45, 104236. Recuperado de

<https://www.sciencedirect.com/science/article/pii/S0882401020305234?via%3DiHub>

Rupal, O. ... [et al.] (2020). High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19. *European Journal of Pharmaceutical Sciences*, 151, 105375, Recuperado de

<https://www.sciencedirect.com/science/article/pii/S0928098720301640?via%3DiHub>

Sajjad, A. ... [et al.] (2020). Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19). *Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics*. *European Journal of Pharmaceutical Sciences*, 151,105387. Recuperado de

<https://www.sciencedirect.com/science/article/pii/S0928098720301767?via%3DiHub>

Thindwa, D. ... [et al.] (2020). Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. *Vaccine*.

Recuperado	de
http://www.sciencedirect.com/science/article/pii/S0264410X20308331	
Usher, A. D. (2020). COVID-19 vaccines for all?, <i>The Lancet</i> , 395, 10240, pp. 1822-1823.	Recuperado de
http://www.sciencedirect.com/science/article/pii/S0140673620313544	
Zhu, F. C. ... [et al.] (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. <i>The Lancet</i> , 395, 10240, pp. 1845-1854.	Recuperado de
http://www.sciencedirect.com/science/article/pii/S0140673620312083	